FLGT - 3 COVID Stocks That Could Double in 2022
The market's a forward-looking mechanism, and some people might feel that the COVID-19 pandemic is "over." That's probably an exaggeration. While vaccinations will hopefully reduce the danger, the virus will continue to mutate, and healthcare companies will continue to fight it. Read more to see why three Fool.com contributors think COVID stocks Fulgent Genetics (NASDAQ: FLGT) , NRx Pharmaceuticals (NASDAQ: NRXP) , and Adaptive Biotechnologies (NASDAQ: ADPT) could double your money this year.
Patrick Bafuma (Fulgent Genetics): Entering the last wave of 2021, you may have heard that there was a run on COVID tests. In fact, just this week, the local CVS told me that there was not an over-the-counter test available within 20 miles. Yet many countries, ports, and employers want the results of a PCR test within three days prior to entry. While this may put a strain on resources, it's great news for RT-PCR test maker Fulgent Genetics.
Image source: Getty Images.
For further details see:
3 COVID Stocks That Could Double in 2022